![[e-mail]](http://wwwcache.wral.com/presentation/v2/images/header/email-15x10.gif){kind=small}
Subscribe
![[e-mail]](http://wwwcache.wral.com/presentation/v1/images/icon_email-story.gif){kind=icon}
Get News Alerts to your Email & Cell Phone
DURHAM, NC — Inspire Pharmaceuticals
will seek to develop a new product for the treatment of rhinitis under a licensing agreement with pharmaceutical firm Boehringer Ingelheim International GmbH, which is based in Germany.
Rhinitis is one of the most common forms of allergic conditions.
Inspire wants to develop an intranasal dosage form of epinastine, the active drug substance it is licensing. Inspire said it wants to begin testing of the drug later this year.
Terms of the deal were not disclosed.
Inspire paid Boehringer Ingelheim an upfront license fee, will fund development efforts, and pay royalties if the drug is approved. The agreement covers Canada and the United States.
![[SLIDESHOW]](http://wwwcache.wral.com/asset/share/2012/02/09/10711513/4f348e7981bb5-51x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/news/local/2012/02/12/10719414/thumbnail-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/entertainment/out_and_about/2012/02/04/10712136/pics_agunn53833-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/entertainment/2012/02/11/10719067/10719072-1329050037-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717011/10717011-1328936455-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717059/10717059-1328939591-100x75.jpg)
WRAL.com welcomes your comments on this story. All comments are moderated prior to publication based on our posting guidelines. Please review them prior to posting and if your message is not approved.
This story is closed for comments. Comments on WRAL.com news stories are accepted and moderated between the hours of 8 a.m. and 8 p.m. Monday through Friday.